Drugs / TG4040
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00529321 | Dec 2006 → Sep 2009 | chronic hepatitis C virus infection | Transgene | Completed | No outcome recorded |
| Phase 1 | NCT00449124 | ? → Sep 2007 | chronic hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01055821 | May 2010 → Oct 2012 | chronic hepatitis C virus infection | Transgene | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG4040 | “TG4040 is a recombinant poxvirus vaccine that expresses the hepatitis C virus (HCV) proteins NS3, NS4, and NS5B.” PMID 21699798 ↗ Jun 2011 |
| Known as | MVA-HCV | “A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and...” NCT01055821 ↗ |
| Modality | Vaccine | “investigational vaccine (TG4040)” NCT00449124 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection into the thigh” NCT00449124 ↗ |